Daniel P. Nampe

Daniel P. Nampe

Auto-generated profile, based on publicly available information

Daniel P. Nampe

Process Development, A2 Biotherapeutics, Inc., 30301 Agoura Road, Agoura Hills, CA 91301, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
MSMark L. Sandberg
Mark L. Sandberg
XWXueyin Wang
Xueyin Wang
AMAaron D. Martin
Aaron D. Martin
DNDaniel P. Nampe
Daniel P. Nampe
GGGrant B. Gabrelow
Grant B. Gabrelow
AKAlexander Kamb
Alexander Kamb
The CEACAM5 gene product [carcinoembryonic antigen (CEA)] is an attractive target for colorectal cancer because of its high expression in virtually all colorectal tumors and limited expression in most healthy adult tissues. However, highly active CEA-directed investigational therapeutics have been reported to be toxic, causing severe colitis because CEA is expressed on normal gut epithelial cells. Here, we developed a strategy to address this toxicity problem: the Tmod dual-signal integrator. CEA Tmod cells use two receptors: a chimeric antigen receptor (CAR) activated by CEA and a leukocyte Ig-like receptor 1 (LIR-1)–based inhibitory receptor triggered by human leukocyte antigen (HLA)-A*02. CEA Tmod cells exploit instances of HLA heterozygous gene loss in tumors to protect the patient from on-target, off-tumor toxicity. CEA Tmod cells potently killed CEA-expressing tumor cells in vitro and in vivo. But in contrast to a traditional CEA-specific T cell receptor transgenic T cell, Tmod cells were highly selective for tumor cells even when mixed with HLA-A*02–expressing cells. These data support further development of the CEA Tmod construct as a therapeutic candidate for colorectal cancer.

9 November 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GHGrace Huang
Grace Huang
DNDaniel Nampe
Daniel Nampe
JYJason Yi
Jason Yi
GGGrant Gabrelow
Grant Gabrelow
KNKathleen Negri
Kathleen Negri
HXHan Xu
Han Xu
Cell therapy is poised to play a larger role in medicine, most notably for immuno-oncology. Despite the recent success of CAR-T therapeutics in the treatment of blood tumors and the rapid progress toward improved versions of both CAR- and TCR-Ts, important analytical aspects of preclinical development and manufacturing of engineered T cells remain immature. One limiting factor is the absence of robust multivariate assays to disentangle key parameters related to function of engineered effector cells, especially in the peptide-MHC (pMHC) target realm, the natural ligand for TCRs. Here we describe an imaging-based primary T cell assay that addresses several of these limitations. To our knowledge, this assay is the first quantitative, high-content assay that separates the key functional parameters of time- and antigen-dependent T cell proliferation from cytotoxicity. We show that the assay sheds light on relevant biology of CAR- and TCR-T cells, including response kinetics and the influence of effector:target ratio.